Skye Bioscience, Inc.
https://www.emeraldbio.life/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Skye Bioscience, Inc.
Skye Biosciences — Advancing Nimacimab In The Anti-Obesity Market
Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Corbus Keeps Rising On ADC And Obesity Plans
The company is on a roll thanks to its challenge to Pfizer’s Padcev and competition with a potential obesity market gamechanger from Novo Nordisk.
Skye Bioscience Looks To Build Appetite For CB1 Obesity Drug
The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Emerald Bioscience, Inc.
- EMBI Australia Pty Ltd.
- Emerald Health Therapeutics, Inc.
- Load Guard Transportation, Inc.
- Load Guard Logistics, Inc.
- Nemus Acquisition Corp., NEMUS Bioscience Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice